Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 5th, 2012 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), is entered into as of August 27, 2012 (the “Effective Date”), by and among Monsanto Company, a Delaware corporation, having a place of business at 800 N. Lindbergh Blvd., St. Louis, Missouri 63167, U.S.A. (“Monsanto”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142, U.S.A. (“Alnylam”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Amended and Restated Strategic Collaboration and License Agreement • November 5th, 2012 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
Novartis Pharma AG Lichtstrasse 35 4056 Basel, SwitzerlandInvestor Rights Agreement • November 5th, 2012 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Reference is made to the Investor Rights Agreement, dated September 6, 2005, by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a corporation organized under the laws of Switzerland (“Novartis,” and together with the Company, the “Parties”) (the “Investor Rights Agreement”).
